GIGABYTE Showcases Comprehensive AI Computing Portfolio at MWC 2025, Leading Industry Transformation from Development to Deployment
GIGABYTE, a global leader in computing innovation and technology, will showcase its full-spectrum AI computing solutions that bridge development to deployment at MWC 2025, taking place from March 3-6.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250223099238/en/
GIGABYTE Showcases Comprehensive AI Computing Portfolio at MWC 2025, Leading Industry Transformation from Development to Deployment (Photo: Business Wire)
“AI+” and “Enterprise-Reinvented” are two of the themes for MWC. As enterprises accelerate their digital transformation and intelligent upgrades, the transition of AI applications from experimental development to democratized commercial deployment has become a critical turning point in the industry. Continuing its "ACCEVOLUTION" initiative, GIGABYTE provides the comprehensive infrastructure products and solutions spanning cloud-based supercomputing centers to edge computing terminals, aiming to accelerate the next evolution and empower industries to scale AI applications efficiently.
Development: High-Performance Scalable Parallel Computing Laying the Foundation for AI Models
GIGABYTE’s close partnerships with industry leaders ensure its position of first-to-market brand offering the most diverse range of AI servers. In response to the continuous evolution of AI chips, GIGABYTE uses its flagship HGX servers design and releases next-gen G893 AI servers to support cutting-edge GPUs like NVIDIA B200, AMD MI325X, and Intel Gaudi-3, with capacity for 12 full-height accelerator cards and full redundant power supply. These servers can be ideal for both cluster operations in data centers and standalone enterprise deployments, advancing intelligent transformation.
GIGABYTE has also launched GIGAPOD, a cluster computing solution for cloud AI data centers, offering a one-stop scalable solution for large AI model training. GIGAPOD can support G893 AI servers while integrating computing and network hardware in a complete rack-level solution, along with optional operating systems and software. The solution encompasses comprehensive services from design, deployment to validation, ensuring efficient AI data center operations. The model showcased at MWC supports NVIDIA B200 and features G4L3 server rack with DLC liquid cooling technology, demonstrating GIGABYTE's readiness for expanding future-proof AI development.
Deployment: Low Latency, Energy Efficiency, and Flexible Edge Computing Solutions Connecting AI's Last Mile
As large models mature, AI is evolving from cloud development toward edge deployment and application, requiring servers and computing solutions focused on flexible implementation and ROI. GIGABYTE's general purpose R-series servers employ CXL technology, which leverages PCIe lanes to coexist with DDR5 memory, enabling memory and resource sharing, enhance bandwidth support, and increase overall operation efficiency with lower space requirements and deployment costs. The X-series servers featuring NVIDIA MGX™ modular design, allowing seamless upgrades to NVIDIA's next-generation GPU platforms by simply replacing the baseboard, ensuring long-term value for enterprise technology investments and facilitating flexible deployment across various edge AI scenarios like smart cities and industrial IoT.
At MWC, GIGABYTE is also showcasing several edge-optimized servers, including EIA-standard edge computing servers with AMD and Intel CPUs, and debuting a new 3U blade server. These servers offer computing options with varying densities and architectures to meet the diverse requirements of edge applications, helping users reduce AI deployment costs and energy consumption while improving computing efficiency.
Through its strong R&D capabilities and close industry partnerships, GIGABYTE has established a complete AI computing ecosystem from cloud to edge. With a comprehensive product line ranging from data center cluster computing solutions to edge computing deployment options, GIGABYTE is a “Game Changer” that enables AI innovation across enterprises and research institutions of all sizes. As AI applications continue to expand, GIGABYTE's full product lineup, supporting the latest generation of computing chips, along with evolving hardware design, software integration, system management, and deployment services, continues to establish a solid foundation for a smarter, more efficient, and scalable future.
More Information https://www.gigabyte.com/Events/MWC
View source version on businesswire.com: https://www.businesswire.com/news/home/20250223099238/en/
Contacts
Media Contact: Michael Pao brand@GIGABYTE.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom